8-K: CDT Equity Secures $1.46M Loan and Restructures Debt

CDT Equity Inc. has entered into a new $1.46 million loan facility with J.J. Astor & Co. to support working capital while eliminating over $6.3 million in legacy debt obligations.

Summary

• CDT Equity Inc. entered into a Loan Agreement with J.J. Astor & Co. for up to $1,460,000 in funding.
• The loan is structured as a senior secured convertible promissory note with an original principal amount of $1,971,000.
• The company received an initial tranche of $268,299.70, with the remaining $1,133,300.30 subject to satisfaction of specific conditions.
• The note is payable in 24 weekly installments of $82,125, starting June 18, 2026.
• The company used proceeds to pay off legacy debt from A.G.P. and Ascent Partners, totaling over $6.3 million in obligations.
• The company issued warrants to the lender to purchase 912,500 shares of common stock at an exercise price of $0.72 per share.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed development; while the company successfully eliminated legacy debt, the new financing is highly dilutive and carries expensive terms that signal continued financial pressure.

Positives

• Elimination of over $6.3 million in legacy financing obligations and liabilities.
• Simplification of the company's capital structure by consolidating debt into a single facility.
• Secured new working capital to support strategic objectives and corporate development.
• Management reports a reduction in outstanding debt by over $4 million since the beginning of 2025.

Negatives

• The loan carries a significant original issue discount, with a $1,971,000 principal amount for $1,460,000 in gross proceeds.
• The company is subject to a 4% origination fee on each tranche.
• The note includes a default interest rate of 19% per annum, compounded daily, if an event of default occurs.
• The company granted a first priority lien on all assets to the lender.
• The company is required to file a resale registration statement by July 26, 2026, and have it effective within 30 days of filing.

Risks

• High dilution risk due to the convertible nature of the note and the issuance of 912,500 warrants.
• Potential for significant share price volatility if the lender converts the note or exercises warrants.
• Strict financial covenants and mandatory prepayment requirements tied to ATM financing proceeds.
• Risk of default if the company fails to meet the second funding conditions by June 30, 2026.
• Nasdaq listing compliance risk, with requirements to maintain minimum bid prices and equity levels.
• The company's public float has declined below $75 million, potentially impacting future financing flexibility.

Future Outlook

The company intends to use the loan proceeds for general working capital and to advance its intellectual property portfolio and strategic partnerships. Management expects to satisfy the conditions for the second funding tranche in June 2026.

Management Comments

• The repayment of these legacy obligations represents an important milestone for CDT.
• We have materially strengthened our balance sheet, reduced outstanding debt by over $4M since the beginning of 2025, and positioned the Company to focus on executing its strategy and creating long-term shareholder value.

Industry Context

StockSavvy.ai notes that this transaction is characteristic of small-cap biopharmaceutical companies utilizing high-cost, dilutive convertible debt to bridge liquidity gaps while attempting to clean up legacy balance sheet issues.

Comparison to Industry Standards

• The use of convertible notes with significant original issue discounts and weekly installment payments is common among distressed micro-cap issuers.
• The 19% default interest rate and 120% default premium are aggressive terms compared to traditional bank financing, reflecting the company's high-risk profile.
• The requirement for shareholder approval for share issuance exceeding 19.99% is standard for Nasdaq-listed companies to comply with exchange rules.

Corporate Governance

Legal Proceedings

• None disclosed beyond standard representations and warranties.

Related Party Transactions

• Covenant Compliance Guaranty Agreement executed by Dr. Andrew Regan, CEO.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of the note and exercise of warrants.
• Lender gains a first priority lien on all company assets, subordinating other creditors.

Next Steps

• Satisfy conditions for the second funding tranche by June 30, 2026.
• File a resale registration statement with the SEC by July 26, 2026.
• Convene a stockholders meeting to obtain approval for share issuance exceeding 19.99%.

Key Dates

Recommendation

The reliance on high-cost, dilutive convertible debt with aggressive default terms and the need for future shareholder approval suggests significant ongoing financial instability and potential for further dilution, which is typically negative for existing equity holders.

Keywords

CDT Equity, Convertible Note, Debt Restructuring, Biopharmaceutical, Financing, Warrants, Capital Structure